Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 9, 2015, Pages E966-E972

  Sagiv Barfi, Idit ^a   Kohrt, Holbrook E K ^a   Czerwinski, Debra K ^a   Ng, Patrick P ^b   Chang, Betty Y ^b   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHARMACYCLICS INC   (United States)

Author keywords

Ibrutinib; Lymphoma; PD 1 PD L1 blockade; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; BRUTON TYROSINE KINASE; GAMMA INTERFERON; IBRUTINIB; INTERLEUKIN 2 INDUCIBLE T CELL KINASE; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; CANCER ANTIBODY; CD274 PROTEIN, MOUSE; EMT PROTEIN-TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE CHECKPOINT; COLON CANCER; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; LUNG METASTASIS; LYMPHOMA; LYMPHOMA CELL; MEMORY T LYMPHOCYTE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; DRUG EFFECTS; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TH1 CELL; TH2 CELL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD274; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; TH1 CELLS; TH2 CELLS;

EID: 84924033378     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1500712112     Document Type: Article

References (28)

1. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90: 297-339.
2. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P (2011) Ipilimumab. Nat Rev Drug Discov 10(6): 411-412.
3. Poole RM (2014) Pembrolizumab: First global approval. Drugs 74(16): 1973-1981.
4. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704.
5. Ohigashi Y, et al. (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8): 2947-2953.
6. Konishi J, et al. (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10(15): 5094-5100.
7. Thompson RH, et al. (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7): 3381-3385.
8. Thompson RH, et al. (2004) Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101(49): 17174-17179.
9. Brahmer JR, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26): 2455-2465.
10. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26): 2443-2454.
11. Hamid O, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2): 134-144.
12. Ansell SM, et al. (2014) PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372(4): 311-319.
13. Wolchok JD, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2): 122-133.
14. Zamarin D, et al. (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226): 226ra32.
15. Cooper ZA, et al. (2014) Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2(7): 643-654.
16. Honigberg LA, et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107(29): 13075-13080.
17. Advani RH, et al. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31(1): 88-94.
18. Barrientos J, Rai K (2013) Ibrutinib: A novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. Leuk Lymphoma 54(8): 1817-1820.
19. Dubovsky JA, et al. (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122(15): 2539-2549.
20. Huang AY, et al. (1996) The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93(18): 9730-9735.
21. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368(14): 1365-1366.
22. Lelekakis M, et al. (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17(2): 163-170.
23. Pulaski BA, Ostrand-Rosenberg S (2001) Mouse 4T1 breast tumor model. Curr Prot Immunol 20: 20.2.
24. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181(8): 5791-5802.
25. Noman MZ, et al. (2014) PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211(5): 781-790.
26. Kim K, et al. (2014) Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA 111(32): 11774-11779.
27. Li J, et al. (2007) Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 179(4): 2493-2500.
28. Shoham T, Rajapaksa R, Kuo CC, Haimovich J, Levy S (2006) Building of the tetraspanin web: Distinct structural domains of CD81 function in different cellular compartments. Mol Cell Biol 26(4): 1373-1385.